This virtual public workshop provided a venue for stakeholders to examine bottlenecks to innovation in drug research and development (R&D) for prevalent chronic diseases and to highlight opportunities ...

Expanded portfolio offerings include first-to-market product launches to support global health challenges New infectious disease research solutions to be spotlighted at ASM Microbe 2025 CORALVILLE, ...

Massimo Radaelli, PhD, is a European pharmaceutical industry leader and entrepreneur who has devoted more than 30 years to the innovation of therapies to treat rare diseases. He is President and CEO ...

Forbes contributors publish independent expert analyses and insights. Greg Licholai writes and teaches about innovation in healthcare. In a move that could dramatically reshape the landscape for rare ...

As I reflect on how we can more effectively bring treatments to patients, one central question emerges: How can we transform scientific discoveries into better treatments? The intersection of science ...

Your editorial on “Why Vinay Prasad Had to Go at FDA” should be a wake-up call for anyone who cares whether federal bureaucrats get to decide if promising new medicines are available to desperately ...

SAN FRANCISCO — On Sunday, Alnylam, the gene-silencing company that notched one gigantic accomplishment after another over ...

DUBLIN--(BUSINESS WIRE)--The "Orphan Drugs - Global Strategic Business Report" report has been added to ResearchAndMarkets.com's offering. The global market for Orphan Drugs was estimated at US$179.5 ...

An inconsistent boom-and-bust cycle funding environment for early-stage biotech innovations and burdensome regulation ...